Skip to main content

Patient’s experience with subcutaneous and oral methotrexate for the treatment of rheumatoid arthritis

By November 2, 2021December 9th, 2021Rheumatoid Arthritis

Methotrexate (MTX) is a prominent treatment for patients with Rheumatoid Arthritis (RA) but its effectiveness may be impacted by bothersome side effects and lack of tolerability. This cross-sectional study by Curtis et al. surveyed RA patients who were members of CreakyJoints who participated in subcutaneous or oral MTX treatment in the last 12 months. 382 patients were surveyed, and they reported side effects such as diarrhea, fatigue, malaise, and hair loss. Higher doses of MTX were associated with a greater likelihood of more side effects.

Click here for more